Suppr超能文献

三碘甲状腺原氨酸与左甲状腺素联合治疗甲状腺功能减退症?

Triiodothyronine alongside levothyroxine in the management of hypothyroidism?

机构信息

Merck Healthcare KGaA, Darmstadt, Germany.

Department of Medicine I, Johannes Gutenberg-University Medical Centre, Mainz, Germany.

出版信息

Curr Med Res Opin. 2021 Dec;37(12):2099-2106. doi: 10.1080/03007995.2021.1984219. Epub 2021 Oct 12.

Abstract

The current guideline-based management of hypothyroidism recommends monotherapy with levothyroxine (LT4), titrated to maintain the level of thyrotropin within a euthyroid reference range. This has been successful for most people with hypothyroidism, but a substantial minority still report symptoms of hypothyroidism unexplained by a comorbid medical condition. LT4 is essentially a prodrug for triiodothyronine (T3), the thyroid hormone that acts on target tissues in the brain and the periphery. Thyroid hormone replacement with LT4 alone does not restore physiological tissue levels of thyroid hormones, particularly T3. During the last two decades, much interest has focussed on the potential of combinations of LT4 and T3 to provide a superior outcome to LT4 monotherapy for people with hypothyroidism, especially those with residual symptoms despite thyrotropin-optimized LT4. This review seeks to provide an overview of currently available evidence on combination (LT4 + T3) therapy to be used for personalized medicine in patients with hypothyroidism. A number of randomized, controlled trials (RCTs) have failed to demonstrate superiority for the combination therapy approach, largely due to non-physiological T3 doses. However, patients with hypothyroidism are highly heterogeneous in terms of their residual thyroid function, individual set points for optimal thyroid homeostasis and for the presence or absence of polymorphisms in deiodinase enzymes in tissues that activate and deactivate circulating thyroid hormones. Accordingly, these RCTs may have failed to demonstrate benefits of combination therapy in individual hypothyroid phenotypes. The pharmacokinetics of LT4 and T3 also differ, which is a barrier to their co-administration. Future clinical trials using LT4 + T3 tablets better suited for combination therapy will resolve the outstanding research questions relating to the place of LT4 + T3 combination therapy in the management of hypothyroidism.

摘要

目前基于指南的甲状腺功能减退症管理建议采用左甲状腺素(LT4)单药治疗,滴定以维持促甲状腺素处于甲状腺功能正常参考范围。对于大多数甲状腺功能减退症患者来说,这种方法是成功的,但仍有相当一部分患者报告有甲状腺功能减退症症状,且无法用并存的医疗状况来解释。LT4 本质上是三碘甲状腺原氨酸(T3)的前体药物,T3 是作用于大脑和外周组织靶器官的甲状腺激素。单独使用 LT4 进行甲状腺激素替代并不能恢复生理组织水平的甲状腺激素,尤其是 T3。在过去的二十年中,人们对 LT4 和 T3 联合应用的潜力产生了浓厚的兴趣,希望其能为甲状腺功能减退症患者,尤其是那些尽管促甲状腺素已优化但仍有残留症状的患者,提供优于 LT4 单药治疗的效果。本综述旨在概述目前关于联合(LT4+T3)治疗用于甲状腺功能减退症患者个体化医学的可用证据。多项随机对照试验(RCT)未能证明联合治疗方法具有优越性,主要原因是 T3 剂量不具有生理学意义。然而,甲状腺功能减退症患者的残余甲状腺功能、最佳甲状腺内稳态的个体设定点以及组织中脱碘酶的存在或缺失存在高度异质性,这些酶可激活和失活循环中的甲状腺激素。因此,这些 RCT 可能未能证明联合治疗在个体甲状腺功能减退表型中的益处。LT4 和 T3 的药代动力学也不同,这是它们联合应用的障碍。未来使用更适合联合治疗的 LT4+T3 片剂进行的临床试验将解决与 LT4+T3 联合治疗在甲状腺功能减退症管理中的地位相关的未决研究问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验